Literature DB >> 1349464

Anesthetic properties of riluzole (54274 RP), a new inhibitor of glutamate neurotransmission.

J Mantz1, A Chéramy, A M Thierry, J Glowinski, J M Desmonts.   

Abstract

It has been suggested that some anesthetic agents could exert their hypnotic/anesthetic effects by selectively blocking receptors involved in the central excitatory neurotransmission mediated by glutamate. In the present study, we analyzed whether riluzole (54274 RP), a novel compound that inhibits both the release and some postsynaptic effects of glutamate in some brain structures, has anesthetic properties in rats. For this purpose, we investigated whether 1) riluzole administered intraperitoneally (ip) at doses ranging from 2.5 to 45 mg/kg induces loss of righting reflex (LRR); 2) riluzole (2.5 and 5 mg/kg) prolongs sleep-times induced by either ketamine (30 or 80 mg/kg ip) or thiopental (25 or 35 mg/kg ip); 3) a 5-mg/kg subanesthetic riluzole dose affects the minimum alveolar concentration of halothane (MACh). Onset of drug action was defined as the period of time from the ip injection to LRR. Sleep-time was considered the period of time from LRR to restoration of righting reflex. Riluzole at doses greater than 15 mg/kg was able to induce LRR (riluzole dose for which LRR was achieved in 50% of the rats [ED50 = 25.6 mg/kg]). A positive correlation was found between the dose of riluzole and sleep-time (r = 0.92, P less than 0.001). A 5-mg/kg (but not 2.5-mg/kg) riluzole dose significantly prolonged sleep-times induced by both ketamine (30 and 80 mg/kg) and thiopental (25 but not 35 mg/kg).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349464     DOI: 10.1097/00000542-199205000-00023

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

Review 2.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

3.  Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.

Authors:  J Marc Simard; Orest Tsymbalyuk; Kaspar Keledjian; Alexander Ivanov; Svetlana Ivanova; Volodymyr Gerzanich
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

4.  Quantum-dot-labeled synuclein seed assay identifies drugs modulating the experimental prion-like transmission.

Authors:  Yukio Imamura; Ayami Okuzumi; Saki Yoshinaga; Akiko Hiyama; Yoshiaki Furukawa; Tomohiro Miyasaka; Nobutaka Hattori; Nobuyuki Nukina
Journal:  Commun Biol       Date:  2022-06-29

5.  Effect of fluoxetine on disease progression in a mouse model of ALS.

Authors:  J E Koschnitzky; K A Quinlan; T J Lukas; E Kajtaz; E J Kocevar; W F Mayers; T Siddique; C J Heckman
Journal:  J Neurophysiol       Date:  2014-03-05       Impact factor: 2.714

6.  Riluzole inhibits spontaneous Ca2+ signaling in neuroendocrine cells by activation of K+ channels and inhibition of Na+ channels.

Authors:  Luis Beltran-Parrazal; Andrew Charles
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

7.  The Sur1-Trpm4 Channel in Spinal Cord Injury.

Authors:  J Marc Simard; Seung Kyoon Woo; Bizhan Aarabi; Volodymyr Gerzanich
Journal:  J Spine       Date:  2013-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.